Background: Subcellular localization modifies H-Ras signaling.
Results: In H-Ras-ablated cells, endomembrane-delimited H-Ras fully reconstitutes vascular endothelial cell growth factor (VEGF)-induced phosphatidylinositol 3-kinase (PI3K)/Akt/endothelial nitric-oxide synthase (eNOS) signaling, eNOS activity, and endothelial cell migration.
Conclusion: Endomembrane H-Ras is sufficient for proangiogenic VEGF signaling.
Significance: Novel endomembrane H-Ras signaling via PI3K/Akt/eNOS constitutes endothelial angiogenic signaling.
Keywords: Angiogenesis, Cell Migration, Nitric Oxide, Nitric-oxide Synthase, Protein Palmitoylation, Vascular Endothelial Growth Factor (VEGF), H-Ras, Endomembrane
Abstract
We demonstrate for the first time that endomembrane-delimited H-Ras mediates VEGF-induced activation of endothelial nitric-oxide synthase (eNOS) and migratory response of human endothelial cells. Using thiol labeling strategies and immunofluorescent cell staining, we found that only 31% of total H-Ras is S-palmitoylated, tethering the small GTPase to the plasma membrane but leaving the function of the large majority of endomembrane-localized H-Ras unexplained. Knockdown of H-Ras blocked VEGF-induced PI3K-dependent Akt (Ser-473) and eNOS (Ser-1177) phosphorylation and nitric oxide-dependent cell migration, demonstrating the essential role of H-Ras. Activation of endogenous H-Ras led to recruitment and phosphorylation of eNOS at endomembranes. The loss of migratory response in cells lacking endogenous H-Ras was fully restored by modest overexpression of an endomembrane-delimited H-Ras palmitoylation mutant. These studies define a newly recognized role for endomembrane-localized H-Ras in mediating nitric oxide-dependent proangiogenic signaling.
Introduction
The small GTPase p21Ras is a major molecular switch, regulating various cellular responses, including proliferation, survival, migration, and apoptosis. After binding GTP, Ras undergoes a conformational change and activates downstream signaling partners by recruiting them to distinct cellular membrane locations. Thus, activation through Ras occurs by interaction with effector Ras-binding domains (RBDs),2 such as that found in Raf and the catalytic subunit p110 of phosphatidylinositol 3-kinase (PI3K) (1). Ras activity is regulated by GTPase-activating proteins that render the protein GDP-bound and thus inactive and guanosine exchange factors that facilitate the GDP/GTP exchange, which activates Ras.
Despite a substantially differing hypervariable region at the C terminus, all three isoforms (H-Ras, K-Ras, and N-Ras) share high sequence homology. Principally, Ras isoforms can interact with the same down-stream effectors, but isoform-specific signaling events are regulated by the expression profile and localization to discrete cellular membranes and microdomains (2, 3). Successful plasma membrane (PM) localization of H-Ras requires at least two different types of post-translational modifications at the C terminus. Farnesylation of cysteine 186, a modification of the CAAX motif and common to all isoforms, weakly tethers Ras to the endoplasmic reticulum. There, the AAX is proteolytically cleaved, and the terminal farnesylated Cys-186 is methylated. In H-Ras, this weak membrane interaction is strengthened by palmitoylation of Cys-181 and Cys-184 in the hypervariable region, resulting in a stable PM localization (4, 5).
At the PM, the thioester bond is hydrolyzed, relocalizing H-Ras to endomembranes, including the Golgi and endoplasmic reticulum (5, 6). The molecular mechanism of H-Ras depalmitoylation, the key enzymes involved, and their regulation are still under investigation (7–9). Despite the long held belief that H-Ras signals exclusively from the PM and PM-derived endosomes (10, 11), constitutively active H-Ras may mediate GTPase signaling at endomembranes, especially the endoplasmic reticulum and Golgi, and two recent publications have demonstrated that this phenomenon occurs with endogenous H-Ras in cell lines (12, 13). To date, functional studies in primary cells have not been performed, and it is unknown whether or not endomembrane H-Ras is involved in physiological endothelial cell (EC) signaling.
For angiogenesis in the adult, the importance of H-Ras signaling is well recognized (14–17). VEGF is a central modulator of angiogenesis in ECs, and its signaling via H-Ras modulates EC function. However, the molecular mechanism through which the VEGF receptor transmits the signal to this isoform remains elusive. VEGF stimulation increases Grb2 association with the receptor (18) and increases Ras GTP loading. However, in ECs, VEGF-induced Raf/MEK/ERK activation is mainly mediated by PKC (19, 20). Nevertheless, GTP-bound H-Ras associates with various downstream effectors important for angiogenesis, including Raf1 and PI3K, which in turn mediate proliferative, migratory, and survival signaling.
Using thiol labeling strategies, we found that 31% of H-Ras was palmitoylated in human aortic endothelial cells (HAECs), leaving the function of the large majority of H-Ras in the cell unexplained. In this study, we demonstrate an essential role of endomembrane H-Ras in EC signaling. By using a non-constitutively active palmitoylation-deficient H-Ras mutant that solely localizes to endomembranes, we found that activation of H-Ras at endomembranes is sufficient for VEGF-mediated signaling that controls the angiogenic response via PI3K, Akt, and eNOS phosphorylation, leading to EC migration.
MATERIALS AND METHODS
Cell Treatments
EC studies were performed with HAECs (Lonza), cultured in complete endothelial growth medium (EGM-2, Lonza) supplemented with 1% penicillin, streptomycin (Invitrogen) and serum-starved overnight in basal endothelial medium (EBM-2 containing 0.1% FBS, Lonza) supplemented with 1% penicillin, streptomycin before experiments. HAECs between passages 8 and 11 were used for all experiments.
Knockdown of endogenous H-Ras was performed with siRNA (Dharmacon) designed against the 3′-untranslated region (ACAGAUGGGAUCACAGUAAUU) and Lipofectamine 2000 (Invitrogen). For ablation of endogenous N-Ras, we used pooled siRNA (Dharmacon, siGENOME, M-003919-00-0005). The validity of the knockdown was assessed after 48–62 h. For efficient knockdown, 90 pmol/ml of siH-Ras and 45 pmol/ml siN-Ras were used. Targeting the 3′-untranslated region of H-Ras allowed for concomitant adenoviral overexpression of H-Ras mutants. Knockdown did not affect cell viability, which was at 97 ± 1.3% for siControl and 98 ± 0.5% for siH-Ras.
H-Ras vectors were generated by subcloning pCMV H-Ras (Clontech) into pcDNA3.1/His-XPRESS (Invitrogen). The palmitoylation-deficient mutant H-Ras PalM was generated by mutating cysteines 181 and 184 to serines using site-directed mutagenesis (Stratagene), and adenoviral vectors were made utilizing the AdEasy system (QBiogene). Adenoviruses were then amplified from single clones, purified according to the manufacturer's protocol, and screened for sequence integrity and the absence of contaminating viral E1A recombination as described previously (21). HAECs were infected with adenoviruses for 48 h before performing assays. After treatment, cells were rinsed with PBS before being lysed into either Laemmli buffer, the respective buffer for measuring eNOS enzyme activity, buffer for enrichment of palmitoylated protein, or fixed in 4% paraformaldehyde for imaging.
RNA Isolation and Quantitative PCR
RNA was isolated using TRIzol (Invitrogen) according to the manufacturer's protocol. RNA was resuspended in RNase/DNase-free water (Fisher), and concentration was measured at 260 nm using a NanoDrop spectrophotometer (Fisher). cDNA was generated by reverse transcription PCR from 1 μg of RNA using the high capacity RNA to cDNA kit (Applied Biosystems).
Quantitative PCR was performed using FAM/NFQ-conjugated TaqMan inventoried assays from Applied Biosystems for human H-Ras (Hs00610483_m1), K-Ras (Hs00270666_m1), and N-Ras (Hs00180035_m1) and murine H-Ras (Mm00476174_m1), K-Ras (Mm00517491_m1), and N-Ras (Mm03053787_m1). The VIC/MGB-labeled β-actin primer/probe set (human, 4326315E; mouse, 4352341E) was used as an internal control, and results were normalized to this Ct value. Quantitative PCR was performed using a StepOnePlus real-time PCR instrument (Applied Biosystems) with the following program: 10-min initial denaturation at 95 °C, followed by 40 cycles of denaturation at 95 °C/15 s and annealing/extension at 60 °C/1 min. ΔΔCt analysis was performed.
Wound Healing/Scratch Assay
Wound healing assays were performed in confluent and quiescent HAECs. All treatments were performed in basal medium containing 0.1% FBS at the time of the scratch, unless otherwise stated. In order to injure the intact monolayer of ECs, a scratch was made with a sterile pipette tip, and pictures were taken at 0 and 16 h at three defined locations of about 15–25 cells each (n = 1). The migration distance was assessed using ImageJ software (National Institutes of Health) as described previously (22). After migration, cells were collected in Laemmli buffer, and knockdown and overexpression were confirmed for each experiment.
Affinity Capture of Palmitoylated Proteins
Palmitoylated proteins were affinity-captured as described previously with some modifications. A confluent 100-cm dish with HAECs was either lysed in reducing, denaturing buffer (20 mm DTT, 1% SDS, 100 mm Tris, pH 7.4) and incubated for 20 min at room temperature to reduce all cysteines or lysed in blocking buffer (100 mm maleimide, 1% SDS, 100 mm Tris pH 7.4) and incubated for 20 min at 50 °C to alkylate all free cysteines. Excess DTT or maleimide was removed using Zeba desalting spin columns (Pierce). For specific thioester hydrolysis and cysteine labeling, the samples were supplemented with 400 mm hydroxylamine, 167 μm HPDP-Biotin (Pierce), 0.5% SDS and incubated for 1 h with agitation at room temperature. Hydrolysis and labeling reactions were terminated by a second desalting step. Biotinylated proteins were purified with magnetic streptavidin-agarose beads (Pierce). The agarose beads were washed four times with PBS containing 0.5% Tween 20, and HPDP-Biotin-modified protein was eluted by boiling with Laemmli buffer (5% 2-mercaptoethanol). The input before and after streptavidin agarose pull-down was resolved on 15% SDS-polyacrylamide gels. Band intensities were measured using ImageJ. A schematic depiction of the method is included in Fig. 3A.
Immunoblotting
Purified proteins following the hydroxylamine-dependent biotin switch assay, eNOS activity assay or unprocessed cell lysates were separated on SDS-polyacrylamide gels and transferred to polyvinylidene fluoride membranes (Immobilon, Millipore), blocked in 5% nonfat milk, and incubated overnight with the respective antibodies. Immunostained membranes for H-Ras (catalog no. ab32417, Abcam), Ras10 (catalog no. 05-516, Millipore), LacZ (β-galactosidase, catalog no. ab616, Abcam) and GAPDH (catalog no. sc25778, Santa Cruz Biotechnology, Inc., Santa Cruz, CA) were incubated with IR dye-conjugated secondary antibodies and visualized using the LI-COR Odyssey system. Membranes probed for phosphorylated (Ser-473, catalog no. 9271, Cell Signaling) and total Akt (catalog no. 2920, Cell Signaling), phosphorylated (Thr-202, Tyr-204, catalog no. 9101, Cell Signaling) and total ERK (catalog no. 9102, Cell Signaling), phosphorylated (Ser-1177, catalog no. 612392, BD Biosciences) and total eNOS (catalog no. 610296, BD Biosciences), and phosphorylated (Ser-239, catalog no. 3114, Cell Signaling) and total VASP (catalog no. 07-1288, Millipore) were developed using HRP-conjugated secondary antibodies and visualized using ECL (GE Healthcare). Band intensities were measured using ImageJ, and values were normalized to GAPDH as a loading control.
Immunohistochemistry
HAECs for immunohistochemistry were grown to 60–80% confluence on polylysine (Sigma)-coated 4-well chamber slides (Nunc). After treatment, cells were rinsed with PBS and fixed in 4% fresh paraformaldehyde for 10 min. Subsequently, cells were washed three times with PBS and permeabilized in 1 mg/ml saponin for 10 min. Cells were blocked for 1 h in 5% IgG and protease-free BSA (Jackson ImmunoResearch) at room temperature and after another three washes incubated overnight at 4 °C in primary antibody supplemented with 0.5% BSA. Unless otherwise stated, overexpressed XPRESS-tagged H-Ras was stained with XPRESS antibody (1:400, Invitrogen), and phospho-eNOS was stained with an antibody against Ser-1177 (1:50, catalog no. 612392, BD Biosciences). The next day, cells were rinsed three times in PBS and then incubated with the secondary antibody anti-mouse Alexa Flour 594 (1:500 in 0.5% BSA) for 1 h at room temperature before being washed another three times. Mounting medium containing DAPI stain (ProLong Gold, Invitrogen) was placed onto the surface of each slide, followed by a coverslip that was then sealed using nail polish. Slides were viewed using an Olympus DSU confocal microscope to determine subcellular distribution of overexpressed H-Ras. A fluorescence (Nikon Eclipse 80i) microscope was also used to image subcellular distribution of eNOS phosphorylation upon stimulation.
Nitric-oxide Synthase Activity Assay
eNOS activity was measured by separating 14C-labeled l-arginine and l-citrulline on thin layer chromatography (TLC) plates as described by Kumar et al. (23). In brief, HAECs treated as indicated were lysed in PBS containing 1% Nonidet P-40 alternative (Millipore), 25 mm NaF, and complete mini protease inhibitor mix (Roche Applied Science). After measuring protein concentration (protein assay, Bio-Rad), 20 μg of protein was added to the 14C-labeled l-arginine-containing reaction mix (23) and incubated at 37 °C for 30 min. The reaction mix contained the following cofactors: β-nicotinamide adenine dinucleotide 2′-phosphate reduced tetrasodium salt (final 2 mm, Sigma), (6R)-5,6,7,8-tetrahydrobiopterin dihydrochloride (final 100 μm, Sigma), CaCl2 (final 1 mm, Sigma), flavin adenine dinucleotide disodium salt hydrate (final 100 μm, Sigma), calmodulin (final 0.05 μg/μl, EMD Millipore). All reagents were dissolved in 30 mm Hepes (pH 7). The reaction was terminated by adding 2 volumes of ice-cold methanol, and precipitated protein was removed by centrifugation. The supernatant was spotted onto a silica gel TLC plate (Sigma), and the product was separated from the substrate using ammonium hydroxide/chloroform/methanol/water (ratio 2:0.5:4.5:1). After chromatography, the separation was visualized, and signals were integrated using the Molecular Imager (Bio-Rad) phosphor imager system. To report VEGF-stimulated eNOS activity, l-citrulline production by non-stimulated cells was subtracted from that of VEGF-stimulated cells, and to account for experimental variations, the results are reported as the percentage of l-citrulline from total signal (l-arginine + l-citrulline).
Ras Activity Assay
Incubation of lysates with an RBD-GST fusion protein allows for a pull-down of active Ras with glutathione-Sepharose beads. Ras activity assays were performed using a Ras activation kit (Jena Bioscience), according to the manufacturer's protocol. In brief, HAECs treated as indicated were lysed into 1 ml of lysis buffer (per 35-mm dish) containing GDP (100 μm) to quench postlytic GTP loading of Ras. Cleared lysates were incubated for 30 min at 4 °C on a rotary shaker with 40 μl of glutathione-Sepharose beads. The beads were spun down and washed one time with 1 ml of lysis buffer. Bound protein was released by boiling in 30 μl of Laemmli buffer (2× concentrated, 5% 2-mercaptoethanol) for 10 min at 95 °C while shaking. Eluted protein was separated on 15% SDS-polyacrylamide gels. Before transferring the separated proteins, the gel containing the pulled-down protein was cut below the 37-kDa protein molecular mass marker, and only the lower half containing H-Ras was transferred to a PVDF membrane and probed for H-Ras. The upper half of the gel was stained with GelCodeBlue (Thermo Scientific) to visualize RBD-GST above the 37-kDa protein marker to control for even distribution of RBD-GST. The ratio of active H-Ras (pull-down) and H-Ras in the lysate (input) was determined by quantifying the bands using ImageJ.
RESULTS
VEGF-induced EC Migration Is H-Ras-dependent
H-Ras is the major isoform in HAECs and in microvascular ECs (murine lung and cardiac ECs), as demonstrated by quantitative RT-PCR of mRNA expression levels (Fig. 1A). The role of H-Ras in EC migration was assessed by siRNA targeting of endogenous H-Ras in HAECs. The siRNA specificity toward H-Ras is shown in Fig. 1B. Although vascular endothelial cell growth factor (VEGF) (50 ng/ml) led to EC cell migration, H-Ras knockdown abolished the promigratory response to VEGF (Fig. 2A).
To ensure that the proangiogenic phenotype is specifically mediated by H-Ras, we depleted HAECs of N-Ras (Figs. 1B and 2B) and measured EC migration in response to VEGF (Fig. 2B). Although N-Ras comprises about 25% of total Ras mRNA in HAECs (Fig. 1A), knockdown of this isoform did not alter the migratory response to VEGF, as demonstrated in Fig. 2B.
Activated H-Ras binds directly to the RBD of PI3K and triggers the formation of phosphatidylinositol 3,4,5-trisphosphate, which controls Akt activity. Akt via specific phosphorylation of eNOS at position Ser-1177 activates the enzyme and enhances •NO production (24–26). Released •NO increases cyclic GMP and activates cGMP-dependent protein kinase activity (PKG), which increases phosphorylation of VASP at Ser-239 (27, 28). In accordance with the migration data, less Akt (Ser-473), eNOS (Ser-1177), and VASP (Ser-239) phosphorylation (Fig. 2, C and D) was observed after knockdown of endogenous H-Ras than in control cells after VEGF stimulation, explaining the molecular mechanism for the loss of migratory response. However, VEGF-mediated activation of ERK 1/2 was unaltered after knockdown of the small GTPase, indicating that utilization of siRNA against H-Ras does not influence VEGF receptor behavior per se. The levels of total protein of Akt, eNOS, VASP, and ERK 1/2 were not affected by siRNA against H-Ras (Fig. 2C).
Consistent with the lack of eNOS phosphorylation at Ser-1177, eNOS activity in H-Ras-depleted cells, measured by conversion of l-arginine to l-citrulline, was attenuated in response to VEGF compared with cells treated with control siRNA (Fig. 2D). These data are consistent with a central role of H-Ras in proangiogenic VEGF signaling of HAECs.
The Majority of H-Ras Is Not Palmitoylated and Resides at Endomembranes
Thioester-linked palmitoylation of cysteines 181 and 184 tethers H-Ras to the PM, whereas unmodified H-Ras accumulates at endomembranes, preferentially at the Golgi, where palmitoyl acyltansferases reside. The hydroxylamine (HA)-dependent biotin switch, a reverse labeling technique for palmitoylated cysteines (see Fig. 3A), was used to determine the ratio of endogenous palmitoylated versus total H-Ras in HAECs. Reducing all reversibly oxidized cysteines with DTT and hydrolyzing the thioester bonds with HA, all 5 cysteines on H-Ras were labeled (Fig. 3B, lane 1). Using HA alone, only palmitoylated cysteines were selectively labeled (Fig. 3B, lane 2). Pull-down of the labeled protein with streptavidin beads followed by SDS-PAGE and immunoblotting against H-Ras showed that only 31% of total endogenous H-Ras in HAECs was palmitoylated (Fig. 3, B and C).
Because the majority of H-Ras in ECs is not palmitoylated, it is expected to localize exclusively to endomembranes (29–31). Accordingly, HAECs moderately overexpressing H-Ras WT showed both PM and endomembrane localization (Fig. 4A, right). Mutation of both palmitoylation sites C181S and C184S (H-Ras PalM), as shown previously in NIH3T3 (31) and MDCK cell lines (30), causes localization of the mutant solely to endomembranes in HAECs (Fig. 4A, left). VEGF-mediated activation of eNOS (phosphorylation at Ser-1177 after 30 min) primarily occurred in the perinuclear region, as shown in Fig. 4, B and C, also indicating endomembrane signaling of eNOS. Thus, the H-Ras PalM mutant serves as a model to study H-Ras function at this subcellular compartment because other proteins necessary in angiogenic signaling, including eNOS, show similar subcellular localization and activation.
Endomembrane-delimited H-Ras Is Sufficient to Mediate VEGF-induced Endothelial Cell Migration
As demonstrated in Fig. 2A, knockdown of endogenous H-Ras inhibits EC migration and signaling caused by VEGF, confirming that H-Ras is required for proangiogenic signaling. Reconstitution of H-Ras-depleted HAECs with the H-Ras PalM mutant restored the migratory phenotype (Fig. 5A). In addition, restoration of the proangiogenic signaling cascade PI3K/Akt/eNOS/VASP also occurred by overexpressing H-Ras PalM (Fig. 5, B and C), indicating that H-Ras at the endomembrane can fully reconstitute proangiogenic signaling by VEGF for induced •NO production and EC migration.
Endomembrane H-Ras Is Sufficient for VEGF-induced Akt and eNOS Phosphorylation and •NO Production
As shown in Fig. 5, reconstitution of H-Ras-depleted HAECs with the endomembrane-localized H-Ras PalM, restored Akt Ser-473 and eNOS Ser-1177 phosphorylation in response to VEGF. Consistent with eNOS activation, the enhanced phosphorylation of VASP at Ser-239 indicates an increase in PKG caused by eNOS-derived •NO (Fig. 2, C and D). Although overexpression of adenoviral H-Ras WT results in increased ERK 1/2 phosphorylation, the main portion of VEGF-mediated activation of the Raf/MEK/ERK cascade is mediated by PKC in EC (19, 20). Conversely, we found that blocking PKC with Gö6983 in HAECs had no effect on VEGF-mediated Akt and eNOS phosphorylation (data not shown). In contrast, inhibition of PI3K with the specific inhibitor LY 294002 prevented VEGF-induced Akt and eNOS phosphorylation as well as EC migration mediated by not only WT but also H-Ras PalM (Fig. 6, A and C), demonstrating the importance of PI3K/Akt/eNOS signaling downstream of endomembrane H-Ras. In addition, treatment of cells with the eNOS inhibitor l-NAME prevented VEGF-induced migration in HAECs depleted of H-Ras and reconstituted with either H-Ras WT or PalM (Fig. 6B), demonstrating that endomembrane H-Ras is sufficient to explain VEGF-induced •NO-mediated EC migration.
VEGF Activates Endomembrane-delimited H-Ras
As demonstrated in Figs. 5 and 6, the palmitoylation-deficient mutant H-Ras PalM is fully capable of mediating VEGF-induced signaling via PI3K/Akt/eNOS and EC migration. However, only GTP-bound H-Ras interacts with its downstream effectors mediating signaling. To support our hypothesis, we measured the ratio of GTP-bound H-Ras to total H-Ras in HAECs stimulated with VEGF over a time course. HAECs depleted of endogenous H-Ras and reconstituted with H-Ras PalM show an increase in endomembrane H-Ras/GTP starting at 30 min with activity persisting over a time period of 2 h. Unlike EGF, which causes H-Ras activation in HEK 293T and HeLa cells within seconds to 5 min (13, 32), VEGF causes a late and sustained activation of endomembrane H-Ras in endothelial cells, mirroring Akt and eNOS phosphorylation/activity (Fig. 7).
DISCUSSION
Here we define a novel role for endomembrane H-Ras in VEGF-induced EC migration. Utilizing a knockdown/reconstitution approach, we show that palmitoylation-deficient H-Ras localized at the endomembranes is preferentially activated by VEGF and fully capable of mediating proangiogenic signaling via PI3K-dependent phosphorylation and activation of Akt and eNOS, enabling EC migration.
Ras isoforms are essential components of growth factor signaling. Although expressed ubiquitously, mRNA levels of the various isoforms appear to be regulated both spatially and temporally. K-Ras knock-out animals are embryonic lethal, whereas N-Ras- and H-Ras-deficient mice show no obvious developmental abnormality (33). However, the importance of H-Ras in post-natal EC angiogenic signaling is undeniable, given its role in differentiating vascular progenitors into ECs stimulated by VEGF (34) and development of capillary-like structures (35). Finally, our results show clearly the essential role of H-Ras in EC migration. Its unique function is further supported, in that depletion of N-Ras shows no impairment of EC migration in response to VEGF (Fig. 2B). The Ras isoform expression profiles of ECs (Fig. 1A) suggest that our model of endomembrane H-Ras signaling in HAECs may also translate into microvascular ECs. HUVECs, however, represent fetal ECs, which express N-Ras as the predominant isoform and exhibit comparably higher levels of K-Ras than aortic and microvascular ECs (Fig. 1A), suggesting differences in Ras signaling.
Serban et al. (16) characterized the role of the two main downstream H-Ras effectors, utilizing constitutively active H-Ras mutants that bind to either Raf or the PI3K catalytic subunit p110. They showed that interaction with Raf alone was capable of mediating angiogenesis, whereas interaction with p110 isoforms increased survival signaling and vascular permeability. In contrast, we modestly overexpressed a non-constitutively active H-Ras (≤10-fold over endogenous H-Ras) that requires the same activating and inactivating factors as the endogenous GTPase. Thus, our studies may better reflect physiological activation of H-Ras by VEGF and proangiogenic downstream effects.
Unlike other growth factors, the requirement for H-Ras in VEGF-mediated activation of the ERK MAPK cascade in ECs is still debated. Although VEGF receptor activation promotes Ras activity via association with adaptor protein Grb2 (18, 19, 36), we and others (20, 37, 38) found that VEGF-induced ERK phosphorylation and downstream signaling strongly depends on PKC activation. Akt and eNOS phosphorylation are, however, unaffected by the PKC inhibitor Gö6983 (data not shown). In support of Ras-mediated Akt signaling in angiogenesis, mice with a defective RBD in p110 show branching defects in their vascular lymphatic system and loss of Akt activation in response to growth factors in cultured mouse embryonic fibroblasts (39).
Several studies investigated eNOS activity and •NO production in response to VEGF at different membrane locations, revealing that eNOS at the PM is sensitive to early calcium-dependent activation, whereas eNOS at the endomembranes shows a delayed response associated with phosphorylation at Ser-1177 by Akt (25, 40–42).
H-Ras interaction with cellular membranes is regulated by C-terminal lipid modifications. Farnesylation at cysteine 186 allows H-Ras to bind to endomembranes but not PM as our (Fig. 4A) and other studies (6, 29, 30) have shown. Single (either Cys-181 or Cys-184) or double S-palmitoylation, however, does lead to PM localization via Golgi vesicular transport. Interestingly, single S-palmitoylated N-Ras and H-Ras (C181S or C184S mutants) show faster depalmitoylation, resulting in shorter PM interaction compared with double S-palmitoylated H-Ras WT (30). Utilizing the palmitoylation-deficient mutant H-Ras PalM, as a model for H-Ras endomembrane signaling, we uncovered a novel VEGF to H-Ras link that omits activation of the small GTPase at the PM and is sufficient for signaling PI3K/Akt/eNOS-mediated migration. Studies in various other cell types reported that wild type and constitutively active endomembrane H-Ras increase ERK signaling upon growth factor stimulation (31, 43, 44). Our studies in adult ECs stimulated with VEGF suggest, however, that ERK is stimulated by PKC, and endomembrane-localized H-Ras is responsible for stimulation of proangiogenic signaling via PI3K/Akt/eNOS. Indeed, our experiments using knockdown/H-Ras PalM reconstitution repeatedly showed increased Akt and eNOS phosphorylation (see Figs. 5 (B and C) and 6C), demonstrating that VEGF can increase eNOS activity via H-Ras at the endomembranes, where it has been reported to cause local oxidative protein modifications, including S-nitrosylation (22, 45). Nevertheless, the signaling mechanism from PM-bound GF receptors to the endomembranes is still in question and may vary in different cell types. Studies in EGF-stimulated COS-1 cells identified the calcium-sensitive Ras GRP1 guanosine exchange factor as an H-Ras activator at the endomembranes and provided evidence that growth factor stimulation of Src/PLCγ activates guanosine exchange factors through increase in local calcium and DAG (12, 46, 47).
By linking endomembrane H-Ras to VEGF-mediated EC migration, our studies have identified a novel mechanism for eNOS activation in adult ECs. We were able for the first time to assign endomembrane H-Ras an active part in EC signaling, relating it to the key PI3K/Akt/eNOS angiogenic signaling pathway that results in nitric oxide production and EC migration.
Acknowledgments
We thank Dr. O. Shirihai and Dr. M. Kirber from the BUMC Cellular Imaging Core for technical assistance and support. We thank Dr. M. Zang for assistance with epifluorescence microscopy. Further, we thank Dr. Melissa D. Thompson and Dr. Jinyang Han for providing mouse lung and cardiac ECs.
This work was supported, in whole or in part, by National Institutes of Health Grants PO1 HL 068758, R37 HL104017, and NHLBI contract number HHSN268201000031C. This work was also supported by a Sir Henry Wellcome postdoctoral fellowship from the Wellcome Trust (Sponsor Reference 085483/Z/08/Z; to J. R. B.).
- RBD
- Ras-binding domain
- PM
- plasma membrane
- l-NAME
- NG-nitro-l-arginine methyl ester
- EC
- endothelial cell
- HAEC
- human aortic endothelial cell
- eNOS
- endothelial nitric-oxide synthase
- VASP
- vasodilator-stimulated phosphoprotein
- HA
- hydroxylamine
- HUVEC
- human umbilical vein endothelial cell
- ANOVA
- analysis of variance.
REFERENCES
- 1. Castellano E., Downward J. (2011) RAS interaction with PI3K. More than just another effector pathway. Genes Cancer 2, 261–274 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 2. Hancock J. F. (2003) Ras proteins. Different signals from different locations. Nat. Rev. Mol. Cell Biol. 4, 373–384 [DOI] [PubMed] [Google Scholar]
- 3. Ahearn I. M., Haigis K., Bar-Sagi D., Philips M. R. (2012) Regulating the regulator. Post-translational modification of RAS. Nat. Rev. Mol. Cell Biol. 13, 39–51 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 4. Swarthout J. T., Lobo S., Farh L., Croke M. R., Greentree W. K., Deschenes R. J., Linder M. E. (2005) DHHC9 and GCP16 constitute a human protein fatty acyltransferase with specificity for H- and N-Ras. J. Biol. Chem. 280, 31141–31148 [DOI] [PubMed] [Google Scholar]
- 5. Henis Y. I., Hancock J. F., Prior I. A. (2009) Ras acylation, compartmentalization, and signaling nanoclusters (Review). Mol. Membr. Biol. 26, 80–92 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 6. Dekker F. J., Rocks O., Vartak N., Menninger S., Hedberg C., Balamurugan R., Wetzel S., Renner S., Gerauer M., Schölermann B., Rusch M., Kramer J. W., Rauh D., Coates G. W., Brunsveld L., Bastiaens P. I., Waldmann H. (2010) Small-molecule inhibition of APT1 affects Ras localization and signaling. Nat. Chem. Biol. 6, 449–456 [DOI] [PubMed] [Google Scholar]
- 7. Belanis L., Plowman S. J., Rotblat B., Hancock J. F., Kloog Y. (2008) Galectin-1 is a novel structural component and a major regulator of h-ras nanoclusters. Mol. Biol. Cell 19, 1404–1414 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 8. Rotblat B., Belanis L., Liang H., Haklai R., Elad-Zefadia G., Hancock J. F., Kloog Y., Plowman S. J. (2010) H-Ras nanocluster stability regulates the magnitude of MAPK signal output. PLoS One 5, e11991. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 9. Ahearn I. M., Tsai F. D., Court H., Zhou M., Jennings B. C., Ahmed M., Fehrenbacher N., Linder M. E., Philips M. R. (2011) FKBP12 binds to acylated h-ras and promotes depalmitoylation. Mol. Cell 41, 173–185 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 10. Willingham M. C., Pastan I., Shih T. Y., Scolnick E. M. (1980) Localization of the src gene product of the Harvey strain of MSV to plasma membrane of transformed cells by electron microscopic immunocytochemistry. Cell 19, 1005–1014 [DOI] [PubMed] [Google Scholar]
- 11. Vieira A. V., Lamaze C., Schmid S. L. (1996) Control of EGF receptor signaling by clathrin-mediated endocytosis. Science 274, 2086–2089 [DOI] [PubMed] [Google Scholar]
- 12. Chiu V. K., Bivona T., Hach A., Sajous J. B., Silletti J., Wiener H., Johnson R. L., 2nd, Cox A. D., Philips M. R. (2002) Ras signalling on the endoplasmic reticulum and the Golgi. Nat. Cell Biol. 4, 343–350 [DOI] [PubMed] [Google Scholar]
- 13. Balla A., Erdélyi L. S., Soltész-Katona E., Balla T., Várnai P., Hunyady L. (2011) Demonstration of angiotensin II-induced Ras activation in the trans-Golgi network and endoplasmic reticulum using bioluminescence resonance energy transfer-based biosensors. J. Biol. Chem. 286, 5319–5327 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 14. Hood J. D., Frausto R., Kiosses W. B., Schwartz M. A., Cheresh D. A. (2003) Differential αv integrin-mediated Ras-ERK signaling during two pathways of angiogenesis. J. Cell Biol. 162, 933–943 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 15. Meadows K. N., Bryant P., Vincent P. A., Pumiglia K. M. (2004) Activated Ras induces a proangiogenic phenotype in primary endothelial cells. Oncogene 23, 192–200 [DOI] [PubMed] [Google Scholar]
- 16. Serban D., Leng J., Cheresh D. (2008) H-ras regulates angiogenesis and vascular permeability by activation of distinct downstream effectors. Circ. Res. 102, 1350–1358 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 17. Bajaj A., Zheng Q., Adam A., Vincent P., Pumiglia K. (2010) Activation of endothelial ras signaling bypasses senescence and causes abnormal vascular morphogenesis. Cancer Res. 70, 3803–3812 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 18. D'Angelo G., Martini J. F., Iiri T., Fantl W. J., Martial J., Weiner R. I. (1999) 16K human prolactin inhibits vascular endothelial growth factor-induced activation of Ras in capillary endothelial cells. Mol. Endocrinol. 13, 692–704 [DOI] [PubMed] [Google Scholar]
- 19. Doanes A. M., Hegland D. D., Sethi R., Kovesdi I., Bruder J. T., Finkel T. (1999) VEGF stimulates MAPK through a pathway that is unique for receptor tyrosine kinases. Biochem. Biophys. Res. Commun. 255, 545–548 [DOI] [PubMed] [Google Scholar]
- 20. Zachary I. (2003) VEGF signalling. Integration and multi-tasking in endothelial cell biology. Biochem. Soc. Trans. 31, 1171–1177 [DOI] [PubMed] [Google Scholar]
- 21. Haeussler D. J., Evangelista A. M., Burgoyne J. R., Cohen R. A., Bachschmid M. M., Pimental D. R. (2011) Checkpoints in adenoviral production. Cross-contamination and E1A. PLoS One 6, e23160. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 22. Evangelista A. M., Thompson M. D., Weisbrod R. M., Pimental D. R., Tong X., Bolotina V. M., Cohen R. A. (2012) Redox regulation of SERCA2 is required for vascular endothelial growth factor-induced signaling and endothelial cell migration. Antioxid. Redox. Signal. 17, 1099–1108 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 23. Kumar V. B., Bernardo A. E., Alshaher M. M., Buddhiraju M., Purushothaman R., Morley J. E. (1999) Rapid assay for nitric oxide synthase using thin-layer chromatography. Anal. Biochem. 269, 17–20 [DOI] [PubMed] [Google Scholar]
- 24. Dimmeler S., Fleming I., Fisslthaler B., Hermann C., Busse R., Zeiher A. M. (1999) Activation of nitric oxide synthase in endothelial cells by Akt-dependent phosphorylation. Nature 399, 601–605 [DOI] [PubMed] [Google Scholar]
- 25. Fulton D., Babbitt R., Zoellner S., Fontana J., Acevedo L., McCabe T. J., Iwakiri Y., Sessa W. C. (2004) Targeting of endothelial nitric-oxide synthase to the cytoplasmic face of the Golgi complex or plasma membrane regulates Akt- versus calcium-dependent mechanisms for nitric oxide release. J. Biol. Chem. 279, 30349–30357 [DOI] [PubMed] [Google Scholar]
- 26. Mount P. F., Kemp B. E., Power D. A. (2007) Regulation of endothelial and myocardial NO synthesis by multi-site eNOS phosphorylation. J. Mol. Cell Cardiol. 42, 271–279 [DOI] [PubMed] [Google Scholar]
- 27. Kawasaki K., Smith R. S., Jr., Hsieh C. M., Sun J., Chao J., Liao J. K. (2003) Activation of the phosphatidylinositol 3-kinase/protein kinase Akt pathway mediates nitric oxide-induced endothelial cell migration and angiogenesis. Mol. Cell Biol. 23, 5726–5737 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 28. Koika V., Zhou Z., Vasileiadis I., Roussos C., Finetti F., Monti M., Morbidelli L., Papapetropoulos A. (2010) PKG-I inhibition attenuates vascular endothelial growth factor-stimulated angiogenesis. Vascul. Pharmacol. 53, 215–222 [DOI] [PubMed] [Google Scholar]
- 29. Rocks O., Gerauer M., Vartak N., Koch S., Huang Z. P., Pechlivanis M., Kuhlmann J., Brunsveld L., Chandra A., Ellinger B., Waldmann H., Bastiaens P. I. (2010) The palmitoylation machinery is a spatially organizing system for peripheral membrane proteins. Cell 141, 458–471 [DOI] [PubMed] [Google Scholar]
- 30. Rocks O., Peyker A., Kahms M., Verveer P. J., Koerner C., Lumbierres M., Kuhlmann J., Waldmann H., Wittinghofer A., Bastiaens P. I. (2005) An acylation cycle regulates localization and activity of palmitoylated Ras isoforms. Science 307, 1746–1752 [DOI] [PubMed] [Google Scholar]
- 31. Cheng C. M., Li H., Gasman S., Huang J., Schiff R., Chang E. C. (2011) Compartmentalized Ras proteins transform NIH 3T3 cells with different efficiencies. Mol. Cell Biol. 31, 983–997 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 32. Rajalingam K., Wunder C., Brinkmann V., Churin Y., Hekman M., Sievers C., Rapp U. R., Rudel T. (2005) Prohibitin is required for Ras-induced Raf-MEK-ERK activation and epithelial cell migration. Nat. Cell Biol. 7, 837–843 [DOI] [PubMed] [Google Scholar]
- 33. Esteban L. M., Vicario-Abejón C., Fernández-Salguero P., Fernández-Medarde A., Swaminathan N., Yienger K., Lopez E., Malumbres M., McKay R., Ward J. M., Pellicer A., Santos E. (2001) Targeted genomic disruption of H-ras and N-ras, individually or in combination, reveals the dispensability of both loci for mouse growth and development. Mol. Cell. Biol. 21, 1444–1452 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 34. Kawasaki K., Watabe T., Sase H., Hirashima M., Koide H., Morishita Y., Yuki K., Sasaoka T., Suda T., Katsuki M., Miyazono K., Miyazawa K. (2008) Ras signaling directs endothelial specification of VEGFR2+ vascular progenitor cells. J. Cell Biol. 181, 131–141 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 35. Miura S., Fujino M., Matsuo Y., Kawamura A., Tanigawa H., Nishikawa H., Saku K. (2003) High density lipoprotein-induced angiogenesis requires the activation of Ras/MAP kinase in human coronary artery endothelial cells. Arterioscler. Thromb. Vasc. Biol. 23, 802–808 [DOI] [PubMed] [Google Scholar]
- 36. Kim C. K., Choi Y. K., Lee H., Ha K. S., Won M. H., Kwon Y. G., Kim Y. M. (2010) The farnesyltransferase inhibitor LB42708 suppresses vascular endothelial growth factor-induced angiogenesis by inhibiting ras-dependent mitogen-activated protein kinase and phosphatidylinositol 3-kinase/Akt signal pathways. Mol. Pharmacol. 78, 142–150 [DOI] [PubMed] [Google Scholar]
- 37. Takahashi T., Ueno H., Shibuya M. (1999) VEGF activates protein kinase C-dependent, but Ras-independent Raf-MEK-MAP kinase pathway for DNA synthesis in primary endothelial cells. Oncogene 18, 2221–2230 [DOI] [PubMed] [Google Scholar]
- 38. Wu L. W., Mayo L. D., Dunbar J. D., Kessler K. M., Baerwald M. R., Jaffe E. A., Wang D., Warren R. S., Donner D. B. (2000) Utilization of distinct signaling pathways by receptors for vascular endothelial cell growth factor and other mitogens in the induction of endothelial cell proliferation. J. Biol. Chem. 275, 5096–5103 [DOI] [PubMed] [Google Scholar]
- 39. Gupta S., Ramjaun A. R., Haiko P., Wang Y., Warne P. H., Nicke B., Nye E., Stamp G., Alitalo K., Downward J. (2007) Binding of ras to phosphoinositide 3-kinase p110α is required for ras-driven tumorigenesis in mice. Cell 129, 957–968 [DOI] [PubMed] [Google Scholar]
- 40. Gélinas D. S., Bernatchez P. N., Rollin S., Bazan N. G., Sirois M. G. (2002) Immediate and delayed VEGF-mediated NO synthesis in endothelial cells. Role of PI3K, PKC and PLC pathways. Br. J. Pharmacol. 137, 1021–1030 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 41. Jobin C. M., Chen H., Lin A. J., Yacono P. W., Igarashi J., Michel T., Golan D. E. (2003) Receptor-regulated dynamic interaction between endothelial nitric oxide synthase and calmodulin revealed by fluorescence resonance energy transfer in living cells. Biochemistry 42, 11716–11725 [DOI] [PubMed] [Google Scholar]
- 42. Gonzalez E., Kou R., Lin A. J., Golan D. E., Michel T. (2002) Subcellular targeting and agonist-induced site-specific phosphorylation of endothelial nitric-oxide synthase. J. Biol. Chem. 277, 39554–39560 [DOI] [PubMed] [Google Scholar]
- 43. Daniels M. A., Teixeiro E., Gill J., Hausmann B., Roubaty D., Holmberg K., Werlen G., Holländer G. A., Gascoigne N. R., Palmer E. (2006) Thymic selection threshold defined by compartmentalization of Ras/MAPK signalling. Nature 444, 724–729 [DOI] [PubMed] [Google Scholar]
- 44. Jin T., Ding Q., Huang H., Xu D., Jiang Y., Zhou B., Li Z., Jiang X., He J., Liu W., Zhang Y., Pan Y., Wang Z., Thomas W. G., Chen Y. (2012) PAQR10 and PAQR11 mediate Ras signaling in the Golgi apparatus. Cell Res. 22, 661–676 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 45. Iwakiri Y., Satoh A., Chatterjee S., Toomre D. K., Chalouni C. M., Fulton D., Groszmann R. J., Shah V. H., Sessa W. C. (2006) Nitric oxide synthase generates nitric oxide locally to regulate compartmentalized protein S-nitrosylation and protein trafficking. Proc. Natl. Acad. Sci. U.S.A. 103, 19777–19782 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 46. Bivona T. G., Pérez De Castro I., Ahearn I. M., Grana T. M., Chiu V. K., Lockyer P. J., Cullen P. J., Pellicer A., Cox A. D., Philips M. R. (2003) Phospholipase Cγ activates Ras on the Golgi apparatus by means of RasGRP1. Nature 424, 694–698 [DOI] [PubMed] [Google Scholar]
- 47. Cullen P. J., Lockyer P. J. (2002) Integration of calcium and Ras signalling. Nat. Rev. Mol. Cell Biol. 3, 339–348 [DOI] [PubMed] [Google Scholar]